In a much-anticipated decision, the FDA approved Eli Lilly’s donanemab. This anti-amyloid antibody is the third drug intended to alter the progression of Alzheimer’s disease treatment. This approval will intensify the competition between Eli Lilly’s Donanemab and Biogen and Eisai’s…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.